Büttner Marcel, Schempf Ulrike, Bachmann Robert, Hoffmann Rüdiger, Schroeder Christopher, Mattern Sven, Singer Stephan, Steinle Marc, Niyazi Maximilian, Bitzer Michael, Gani Cihan
Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
Department of Internal Medicine I, University Hospital Tuebingen 72076 Tuebingen, Germany.
Clin Transl Radiat Oncol. 2025 Apr 9;53:100953. doi: 10.1016/j.ctro.2025.100953. eCollection 2025 Jul.
We report the case of a 57-year-old male patient who presented with a circumferential cT3 cN1 rectal adenocarcinoma in the mid rectum. The tumor was found to be mismatch repair deficient/microsatellite instable (dMMR/MSI). Instead of multimodality treatment with chemoradiotherapy immunotherapy with Dostarlimab was initiated. Treatment was well-tolerated in general and endoscopy and MRI showed early signs of treatment response. Despite this, the patient developed intestinal obstruction due to scarring that required repeat balloon dilations. In contrast to other oncological treatments, obstructions may worsen during immunotherapy in dMMR rectal cancers. This information has to be considered when patients are consulted regarding the optimal treatment after disease.
我们报告了一例57岁男性患者,其直肠中段出现环周性cT3 cN1直肠腺癌。发现该肿瘤为错配修复缺陷/微卫星不稳定(dMMR/MSI)。未采用放化疗的多模式治疗,而是开始使用度伐利尤单抗进行免疫治疗。总体而言,治疗耐受性良好,内镜检查和磁共振成像显示出早期治疗反应迹象。尽管如此,患者因瘢痕形成出现肠梗阻,需要反复进行球囊扩张。与其他肿瘤治疗不同,dMMR直肠癌在免疫治疗期间梗阻情况可能会恶化。在就疾病后的最佳治疗咨询患者时,必须考虑这一信息。